/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $128.7 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases. The biotechnology company is expected to announce its fiscal third-quarter earnings for 2024 after the market closes on Monday, Nov. 4.
Ahead of the event, analysts expect VRTX to report a profit of $3.61 per share on a diluted basis, down 1.6% from $3.67 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing on other two occasions.